medigraphic.com
Instituto Nacional de Salud Pública

2013, Number 2

<< Back Next >>

salud publica mex 2013; 55 (2)

HPV vaginal self-sampling among women non-adherent to Papanicolaou screening in Chile

Léniz J, Barriga MI, Lagos M, Ibáñez C, Puschel K, Ferreccio C

Language: English
References: 33
Page: 162-169
PDF size: 325.96 Kb.


ABSTRACT

Objective. To evaluate acceptance, preference and compliance with referral of vaginal self-sampling for the detection of Human papillomavirus (HPV) among women non-adherent to Papanicolaou (Pap) screening in Santiago, Chile. Materials and methods. Using multistage sampling we identified women aged 30-64 years who reported not receiving a Pap test in the previous three years and offered them Pap testing at the health center or vaginal self-sampling for HPV testing at home. Self-collected samples were analyzed with hybrid capture. All HPV+ women were referred for colposcopy, biopsy and treatment when needed. Results. 1 254 eligible women were contacted; 86.5% performed self-sampling and 8.1% refused; 124 women were HPV+ (11.4%: 95%CI 9.6-13.5) of whom 85.5% attended colposcopy; 12 had CIN2+ (1.1%: 95 %CI 0.5-1.7). Conclusion. HPV vaginal self-sampling can be easily implemented in Chile and could improve coverage, successfully reaching women who drop out of the screening program.


REFERENCES

  1. World Health Organization. (WHO) 2008. The globocan project [Accessed October 20, 2011] Available at: http://globocan.iarc.fr

  2. Parkin DM, Almonte M, Bruni L, Clifford G, Curado MP, Pineros M. Burden and trends of type-specific human papillomavirus infections and related diseases in the Latin America and Caribbean region. Vaccine 2008;26 S11:L1-L15.

  3. van der Aa MA, Pukkala E, Coebergh JW, Anttila A, Siesling S. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. Int J Cancer 2008;122:1854-1858.

  4. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004;364:249-256.

  5. Departamento de Estadísticas e Información de Salud. (Ministerio de Salud de Chile). [Accessed September 17, 2011] Available at: http://deis.minsal.cl)

  6. Ferreccio C, Van De Wyngard V, Olcay F, Domínguez MA, Puschel K, Corvalán AH, et al. High-risk HPV infection after five years in a population-based cohort of Chilean women. Infect Agent Cancer 2011;6:21.

  7. Ministerio de Salud de Chile, Departamento de Estadísticas e Información de Salud. Cobertura (%) PAP vigente en mujeres beneficiarias de 25 a 64 años, según Servicio de Salud. SNSS 2008-2009. [Accessed June 8, 2012] Available at: http://deis.minsal.cl/cobertura/PAP/CoberturaPAP_SNSS.htm

  8. Urrutia MT, Poupin L, Concha X, Viñales D, Iglesias C, Reyes V. ¿Por qué las mujeres no se toman el Papanicolau?: Barreras percibidas por un grupo de mujeres ingresadas al programa de cáncer cervicouterino AUGE. Rev chil obstet ginecol 2008;73:98-103.

  9. Urrutia MT. Creencias sobre Papanicolaou y cáncer cérvicouterino en un grupo de mujeres chilenas. Rev Chil Obstet Ginecol 2012;77:3-10.

  10. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural india. N Engl J Med 2009;360:1385-1394.

  11. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005;353:2158-2168.

  12. Flores YN, Bishai DM, Lorincz A, Shah KV, Lazcano-Ponce E, Hernandez M, et al. HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico. Cancer Causes Control 2011;22:261-272.

  13. Petignat P, Faltin DL, Bruchim I, Tramer MR, Franco EL, Coutlee F. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol 2007;105:530-535.

  14. Brink AATP, Meijer CJLM, Wiegerinck MAHM, Nieboer TE, Kruitwagen RFPM, van Kemenade F, et al. High concordance of results of testing for human papillomavirus in cervicovaginal samples collected by two methods, with comparison of a novel self-sampling device to a conventional endocervical brush. J Clin Microbiol 2006;44:2518-2523.

  15. Salmeron J, Lazcano-Ponce E, Lorincz A, Hernandez M, Hernandez P, Leyva A, et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos state, Mexico. Cancer Causes Control 2003;14:505-512.

  16. Szarewski A, Cadman L, Mallett S, Austin J, Londesborough P, Waller J, et al. Human papillomavirus testing by self-sampling: Assessment of accuracy in an unsupervised clinical setting. J Med Screen 2007;14:34-42.

  17. Bais AG, van Kemenade FJ, Berkhof J, Verheijen RH, Snijders PJ, Voorhorst F, et al. Human papillomavirus testing on self-sampled cervicovaginal brushes: An effective alternative to protect nonresponders in cervical screening programs. Int J Cancer 2007;120:1505-1510.

  18. Dzuba IG, Diaz EY, Allen B, Leonard YF, Lazcano-Ponce EC, Shah KV, et al. The acceptability of self-collected samples for HPV testing vs. the Pap test as alternatives in cervical cancer screening. J Womens Health Gend Based Med 2002;11:265-275.

  19. Ministerio de Desarrollo Social de Chile. Encuesta CASEN 2009. [Accessed June 8, 2012] Available at: http://www.ministeriodesarrollosocial.gob.cl/casen/index.html#

  20. Meijer CJ, Berkhof J, Castle PE, Hessenlink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cáncer screening in women of 30 years and older. Int J Cancer 2009;124:516-520.

  21. Ferreccio C, Prado R, Luzoro A, Ampuero S, Snijders P, Meijer Ch, et al. Population-Based Prevalence and Age Distribution of Human Papillomavirus Among Women in Santiago, Chile. Cancer Epidemiol Biomarkers Prev 2004;13(12):2271-226.

  22. Odongua N, Chae YM, Kim MR, Yun JE, Jee SH. Associations between smoking, screening, and death caused by cervical cancer in Korean women. Yonsei Med J 2007;48:192-200.

  23. Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, et al. Screening-preventable cervical cancer risks: Evidence from a nationwide audit in Sweden. J Natl Cancer Inst 2008;100:622-629.

  24. Wikstrom I, Stenvall H, Wilander E. Attitudes to self-sampling of vaginal smear for human papilloma virus analysis among women not attending organized cytological screening. Acta Obstet Gynecol Scand 2007;86:720-725.

  25. Giorgi Rossi P, Marsili LM, Camilloni L, Iossa A, Lattanzi A, Sani C, et al. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: A randomised controlled trial (ISRCTN96071600). Br J Cancer 2011;104:248-254.

  26. Gage JC, Ferreccio C, Gonzales M, Arroyo R, Huivin M, Robles SC. Follow-up care of women with an abnormal cytology in a low-resource setting. Cancer Detect Prev 2003;27:466-471.

  27. Kinlen LJ, Spriggs, AI. Women with positive cervical smears but without surgical intervention. Lancet 1978;312:463-465.

  28. Suarez E, Prieto M, Rojas I, Fernandez B, Prado R, Olfos P. Programa nacional de cáncer cervicouterino. Rev Chil Obstet Ginecol 2001;66:480.

  29. Arellano R. Sobrevivencia en cáncer cervicouterino. Servicio de Salud Metropolitano Sur Oriente. Tesis para optar al grado de Magíster en Salud Pública. Escuela de Salud Pública Facultad de Medicina Universidad de Chile. [Accessed May 22, 2012] Available at: http://campusesp.uchile.cl:8080/dspace/bitstream/123456789/152/1/Ruth%20Arellano_MSP20--.pdf

  30. Gok M, Heideman DA, van Kemenade FJ, Berkhof J, Rozendaal L, Spruyt JW, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. Brit Med J 2010;340:c1040.

  31. Almonte M, Murillo R, Sanchez GI, Jeronimo J, Salmeron J, Ferreccio C, et al. New paradigms and challenges in cervical cancer prevention and control in Latin America. Salud Publica Mex 2010;52:544-559.

  32. Schmeink CE, Bekkers RL, Massuger LF, Melchers WJ. The potential role of self-sampling for high-risk human papillomavirus detection in cervical cancer screening. Rev Med Virol 2011;21:139-153.

  33. Belinson JL, Du H, Yang B, Wu R, Belinson SE, Qu X, et al. Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing. Int J Cancer 2012;130:1855-1860.




2020     |     www.medigraphic.com